-
1
-
-
0036229958
-
Specific cyclooxygenase-2 inhibitors: What have we learned since they came into widespread clinical use
-
Crofford LJ: Specific cyclooxygenase-2 inhibitors: what have we learned since they came into widespread clinical use. Curr Opin Rheumatol (2002) 14: 225-230.
-
(2002)
Curr Opin Rheumatol
, vol.14
, pp. 225-230
-
-
Crofford, L.J.1
-
2
-
-
0035833502
-
The coxibs, selective inhibitors of cyclooxygenase-2
-
Fitzgerald GA and Patrono C: The coxibs, selective inhibitors of cyclooxygenase-2. N Eng J Med (2001) 345: 433-442.
-
(2001)
N Eng J Med
, vol.345
, pp. 433-442
-
-
Fitzgerald, G.A.1
Patrono, C.2
-
3
-
-
0032948948
-
Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids
-
Catella-Lawson F, McAdam B, Morrison BW, Kapoor S, Kujubu D, Antes L, Lasseter KC, Quan H, Gertz BJ and FitzGerald GA: Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp Ther (1999) 289: 735-741.
-
(1999)
J Pharmacol Exp Ther
, vol.289
, pp. 735-741
-
-
Catella-Lawson, F.1
McAdam, B.2
Morrison, B.W.3
Kapoor, S.4
Kujubu, D.5
Antes, L.6
Lasseter, K.C.7
Quan, H.8
Gertz, B.J.9
FitzGerald, G.A.10
-
4
-
-
0033524421
-
Systemic biosynthesis of prostacyclin by COX-2: The human pharmacology of a selective inhibitor of COX-2
-
McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA and FitzGerald GA: Systemic biosynthesis of prostacyclin by COX-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci USA (1999) 96: 272-277.
-
(1999)
Proc Natl Acad Sci USA
, vol.96
, pp. 272-277
-
-
McAdam, B.F.1
Catella-Lawson, F.2
Mardini, I.A.3
Kapoor, S.4
Lawson, J.A.5
FitzGerald, G.A.6
-
5
-
-
0035910976
-
Cyclooxygenase inhibition and thrombogenicity
-
Catella-Lawson F and Crofford LJ: Cyclooxygenase inhibition and thrombogenicity. Am J Med (2001) 110: 28S-32S.
-
(2001)
Am J Med
, vol.110
-
-
Catella-Lawson, F.1
Crofford, L.J.2
-
6
-
-
0035859802
-
Effects of selective cyclooxygenase-2 inhibition on vascular responses and thrombosis in canine coronary arteries
-
Hennan JK, Huang J, Barret TD, Driscoll EM, Willens DE, Park AM, Crofford LJ and Lucchesi BR: Effects of selective cyclooxygenase-2 inhibition on vascular responses and thrombosis in canine coronary arteries. Circulation (2001) 104: 820-825.
-
(2001)
Circulation
, vol.104
, pp. 820-825
-
-
Hennan, J.K.1
Huang, J.2
Barret, T.D.3
Driscoll, E.M.4
Willens, D.E.5
Park, A.M.6
Crofford, L.J.7
Lucchesi, B.R.8
-
7
-
-
0033898782
-
Thrombosis in patients with connective tissue disease treated with specific cyclooxygenase-2 inhibitors. A report of four cases
-
Crofford LJ, Oates JC, McCune WJ, Gupta S, Kaplan MJ, Catella-Lawson F, Morrow JD, McDonagh KT and Schmaier AH: Thrombosis in patients with connective tissue disease treated with specific cyclooxygenase-2 inhibitors. A report of four cases. Arthritis Rheum (2000) 43: 1891-1896.
-
(2000)
Arthritis Rheum
, vol.43
, pp. 1891-1896
-
-
Crofford, L.J.1
Oates, J.C.2
McCune, W.J.3
Gupta, S.4
Kaplan, M.J.5
Catella-Lawson, F.6
Morrow, J.D.7
McDonagh, K.T.8
Schmaier, A.H.9
-
8
-
-
0037027050
-
COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease
-
Ray WA, Stein CM, Daugherty JR, Hall K, Arbogast PG and Griffin MR: COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet (2002) 360: 1071-1073.
-
(2002)
Lancet
, vol.360
, pp. 1071-1073
-
-
Ray, W.A.1
Stein, C.M.2
Daugherty, J.R.3
Hall, K.4
Arbogast, P.G.5
Griffin, M.R.6
-
9
-
-
0034707105
-
VIGOR Study Group: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis
-
Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvien TK and Schnitzer TJ: VIGOR Study Group: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med (2000) 343: 1520-1528.
-
(2000)
N Engl J Med
, vol.343
, pp. 1520-1528
-
-
Bombardier, C.1
Laine, L.2
Reicin, A.3
Shapiro, D.4
Burgos-Vargas, R.5
Davis, B.6
Day, R.7
Ferraz, M.B.8
Hawkey, C.J.9
Hochberg, M.C.10
Kvien, T.K.11
Schnitzer, T.J.12
-
10
-
-
0035818601
-
Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib
-
Konstam MA, Weir MR, Reicin A, Shapiro D, Sperling RS, Barr E and Gertz BJ: Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation (2001) 104: 2280-2288.
-
(2001)
Circulation
, vol.104
, pp. 2280-2288
-
-
Konstam, M.A.1
Weir, M.R.2
Reicin, A.3
Shapiro, D.4
Sperling, R.S.5
Barr, E.6
Gertz, B.J.7
-
11
-
-
0035913126
-
Measurement of endothelial function by brachial artery flow-mediated vasodilation
-
Vogel R: Measurement of endothelial function by brachial artery flow-mediated vasodilation. Am J Cardiol (2001) 88: 31E-34E.
-
(2001)
Am J Cardiol
, vol.88
-
-
Vogel, R.1
-
12
-
-
0037469296
-
Selective COX-2 inhibition improves endothelial function in coronary artery disease
-
Chenevard R, Hurlimann D, Bechir M, Enseleit F, Spieker L, Hermann M, Riesen W, Gay S, Gay RE, Neidhart M, Michel B, Luscher TF, Noll G and Ruschitzka F: Selective COX-2 inhibition improves endothelial function in coronary artery disease. Circulation (2003) 107: 405-409.
-
(2003)
Circulation
, vol.107
, pp. 405-409
-
-
Chenevard, R.1
Hurlimann, D.2
Bechir, M.3
Enseleit, F.4
Spieker, L.5
Hermann, M.6
Riesen, W.7
Gay, S.8
Gay, R.E.9
Neidhart, M.10
Michel, B.11
Luscher, T.F.12
Noll, G.13
Ruschitzka, F.14
-
13
-
-
0035846658
-
Cyclooxygenase-2 blockade does not impair endothelial vasodilator function in healthy volunteers: Randomized evaluation of rofecoxib versus naproxen on endothelium-dependent vasodilatation
-
Verma S, Raj SR, Shewchuk L, Mather KJ and Anderson TJ: Cyclooxygenase-2 blockade does not impair endothelial vasodilator function in healthy volunteers: Randomized evaluation of rofecoxib versus naproxen on endothelium-dependent vasodilatation. Circulation (2001) 104: 2879-2882.
-
(2001)
Circulation
, vol.104
, pp. 2879-2882
-
-
Verma, S.1
Raj, S.R.2
Shewchuk, L.3
Mather, K.J.4
Anderson, T.J.5
-
14
-
-
0242460486
-
Effect of cyclooxygenase-2 inhibition with rofecoxib on endothelial dysfunction and inflammatory markers in patients with coronary artery disease
-
Title LM, Giddens K, McInerney MM, McQueen MJ and Nassar BA: Effect of cyclooxygenase-2 inhibition with rofecoxib on endothelial dysfunction and inflammatory markers in patients with coronary artery disease. J Am Coll Cardiol (2003) 42: 1747-1753.
-
(2003)
J Am Coll Cardiol
, vol.42
, pp. 1747-1753
-
-
Title, L.M.1
Giddens, K.2
McInerney, M.M.3
McQueen, M.J.4
Nassar, B.A.5
-
15
-
-
0026478022
-
Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis
-
Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID, Lloyd JK and Deanfield JE: Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet (1992) 340: 1111-1115.
-
(1992)
Lancet
, vol.340
, pp. 1111-1115
-
-
Celermajer, D.S.1
Sorensen, K.E.2
Gooch, V.M.3
Spiegelhalter, D.J.4
Miller, O.I.5
Sullivan, I.D.6
Lloyd, J.K.7
Deanfield, J.E.8
-
16
-
-
0037028635
-
Why do cyclo-oxygenase-2 inhibitors cause cardiovascular events
-
Bing RJ and Lomnicka M: Why do cyclo-oxygenase-2 inhibitors cause cardiovascular events. J Am Coll Cardiol (2002) 39: 521-522.
-
(2002)
J Am Coll Cardiol
, vol.39
, pp. 521-522
-
-
Bing, R.J.1
Lomnicka, M.2
-
17
-
-
0034644396
-
Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study
-
Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson WF, Burr AM, Zhao WW, Kent JD, Lefkowith JB, Verburg KM and Geis GS: Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA (2000) 284: 1247-1255.
-
(2000)
JAMA
, vol.284
, pp. 1247-1255
-
-
Silverstein, F.E.1
Faich, G.2
Goldstein, J.L.3
Simon, L.S.4
Pincus, T.5
Whelton, A.6
Makuch, R.7
Eisen, G.8
Agrawal, N.M.9
Stenson, W.F.10
Burr, A.M.11
Zhao, W.W.12
Kent, J.D.13
Lefkowith, J.B.14
Verburg, K.M.15
Geis, G.S.16
-
18
-
-
0032869042
-
Assessment and treatment of endothelial dysfunction in humans
-
Anderson TJ: Assessment and treatment of endothelial dysfunction in humans. J Am Coll Cardiol (1999) 34: 631-638.
-
(1999)
J Am Coll Cardiol
, vol.34
, pp. 631-638
-
-
Anderson, T.J.1
-
19
-
-
0034617245
-
The effect of aspirin and two nitric oxide donors on the infarcted heart in situ
-
Yamamoto T, Kakar NR, Vina ER, Johnson PE and Bing RJ: The effect of aspirin and two nitric oxide donors on the infarcted heart in situ. Life Sci (2000) 67: 839-846.
-
(2000)
Life Sci
, vol.67
, pp. 839-846
-
-
Yamamoto, T.1
Kakar, N.R.2
Vina, E.R.3
Johnson, P.E.4
Bing, R.J.5
-
20
-
-
0034900837
-
Effects of COX-2 inhibitors on aortic prostacyclin production in cholesterol-fed rabbits
-
Wong E, Huang J, Tagari P and Riendeau D: Effects of COX-2 inhibitors on aortic prostacyclin production in cholesterol-fed rabbits. Atherosclerosis (2001) 157: 393-402.
-
(2001)
Atherosclerosis
, vol.157
, pp. 393-402
-
-
Wong, E.1
Huang, J.2
Tagari, P.3
Riendeau, D.4
-
21
-
-
0033015661
-
Cyclooxygenase-2 is widely expressed in atherosclerotic lesions affecting native and transplanted human coronary arteries and colocalizes with inducible nitric oxide synthase and nitrotyrosine particularly in macrophages
-
Baker CS, Hall RJ, Evans TJ, Pomerance A, Maclouf J, Creminon C, Yacoub MH and Polak JM: Cyclooxygenase-2 is widely expressed in atherosclerotic lesions affecting native and transplanted human coronary arteries and colocalizes with inducible nitric oxide synthase and nitrotyrosine particularly in macrophages. Arterioscler Thromb Vasc Biol (1999) 19: 646-655.
-
(1999)
Arterioscler Thromb Vasc Biol
, vol.19
, pp. 646-655
-
-
Baker, C.S.1
Hall, R.J.2
Evans, T.J.3
Pomerance, A.4
Maclouf, J.5
Creminon, C.6
Yacoub, M.H.7
Polak, J.M.8
-
22
-
-
0032833967
-
Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions
-
Schonbeck U, Sukhova GK, Graber P, Coulter S and Libby P: Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. Am J Pathol (1999) 155: 1281-1291.
-
(1999)
Am J Pathol
, vol.155
, pp. 1281-1291
-
-
Schonbeck, U.1
Sukhova, G.K.2
Graber, P.3
Coulter, S.4
Libby, P.5
-
23
-
-
0037047092
-
Cyclooxygenase-2 inhibition and cardiovascular events
-
Pitt B, Pepine C and Willerson JT: Cyclooxygenase-2 inhibition and cardiovascular events. Circulation (2002) 106: 167-169.
-
(2002)
Circulation
, vol.106
, pp. 167-169
-
-
Pitt, B.1
Pepine, C.2
Willerson, J.T.3
-
24
-
-
0037143638
-
A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis
-
Verma S, Wang CH, Li SH, Dumont AS, Fedak PW, Badiwala MV, Dhillon B, Weisel RD, Li RK, Mickle DA and Stewart DJ: A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation (2002) 106: 913-919.
-
(2002)
Circulation
, vol.106
, pp. 913-919
-
-
Verma, S.1
Wang, C.H.2
Li, S.H.3
Dumont, A.S.4
Fedak, P.W.5
Badiwala, M.V.6
Dhillon, B.7
Weisel, R.D.8
Li, R.K.9
Mickle, D.A.10
Stewart, D.J.11
-
25
-
-
0037022910
-
Inflammation and atherosclerosis
-
Libby P, Ridker PM and Maseri A: Inflammation and atherosclerosis. Circulation (2002) 105: 1135-1143.
-
(2002)
Circulation
, vol.105
, pp. 1135-1143
-
-
Libby, P.1
Ridker, P.M.2
Maseri, A.3
-
26
-
-
0033966627
-
Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary artery disease (BANNF Study)
-
Anderson TJ, Elstein E, Haber H and Charbonneau F: Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary artery disease (BANNF Study). J Am Coll Cardiol (2000) 35: 60-66.
-
(2000)
J Am Coll Cardiol
, vol.35
, pp. 60-66
-
-
Anderson, T.J.1
Elstein, E.2
Haber, H.3
Charbonneau, F.4
-
27
-
-
0036499185
-
Effect of losartan in aging-related endothelial impairment
-
Rajagopalan S, Brook R, Mehta RH, Supiano M and Pitt B: Effect of losartan in aging-related endothelial impairment. Am J Cardiol (2002) 89: 562-566.
-
(2002)
Am J Cardiol
, vol.89
, pp. 562-566
-
-
Rajagopalan, S.1
Brook, R.2
Mehta, R.H.3
Supiano, M.4
Pitt, B.5
|